Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi‑1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP

Kong,Xiaoyang; Luo,Jing; Xu,Tongpeng; Zhou,Yunjiao; Pan,Zengkai; Xie,Yinghua; Zhao,Limin; Lu,Yingting; Han,Xiyao; Li,Zhixiong; Liu,Ligen

doi:10.3892/or.2017.5627

Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi‑1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP

Authors:
- Xiaoyang Kong
- Jing Luo
- Tongpeng Xu
- Yunjiao Zhou
- Zengkai Pan
- Yinghua Xie
- Limin Zhao
- Yingting Lu
- Xiyao Han
- Zhixiong Li
- Ligen Liu
View Affiliations

Affiliations: Department of Hematology, Shanghai No. 5 Hospital, Fudan University, Shanghai 200240, P.R. China, Central Laboratory, Shanghai No. 5 Hospital, Fudan University, Shanghai 200240, P.R. China, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, D-30625 Hannover, Germany
Published online on: May 4, 2017 https://doi.org/10.3892/or.2017.5627
Pages: 3423-3432

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although the patients with t(8;21) acute myeloid leukemia (AML) have a favorable prognosis compared with other non-acute promyelocytic leukemia AML patients, only ~50% patients with this relatively favorable subtype can survive for 5 years and refractory/relapse is common in clinical practice. So it is necessary to find novel agents to treat this type of AML. In this study, the effects and the mechanisms of plumbagin and recombinant soluble tumor necrosis factor‑α-related apoptosis-inducing ligand (rsTRAIL) on leukemic Kasumi‑1 cells were primarily investigated. Plumbagin and/or rsTRAIL could significantly inhibit the growth of Kasumi‑1 cells and induce apoptosis in vitro and in vivo. Plumbagin enhanced TRAIL-induced apoptosis of Kasumi‑1 cells in association with mitochondria damage, caspase activation, upregulation of death receptors (DRs) and decreased cFLIP expression. The effects of plumbagin on the expression of DR5, Bax and cFLIP could be partially abolished by the reactive oxygen species (ROS) scavenger NAC. Glutathione (GSH) depletion by plumbagin increased the production of ROS. In vivo, there was no obvious toxic pathologic change in the heart, liver and kidney tissues in any of the groups. Comparing with the control mice, a significantly increased number of apoptotic cells were observed in the combined treated mice by flow cytometry. Plumbagin also increased the expression of DR4 and DR5 in cells of xenograft tumors. Collectively, our results suggest that both plumbagin and rsTRAIL could be used as a single agent or synergistical agents to induce apoptosis of leukemic Kasumi‑1 cells in vitro and in vivo.

View Figures

View References

1	LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10:66–75. 2003. View Article : Google Scholar : PubMed/NCBI
2	Mahalingam D, Szegezdi E, Keane M, de Jong S and Samali A: TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
3	Sessler T, Healy S, Samali A and Szegezdi E: Structural determinants of DISC function: New insights into death receptor-mediated apoptosis signalling. Pharmacol Ther. 140:186–199. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ashkenazi A, Holland P and Eckhardt SG: Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 26:3621–3630. 2008. View Article : Google Scholar : PubMed/NCBI
5	Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
6	Zhang L and Fang B: Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
7	Van Geelen CMM, de Vries EGE and de Jong S: Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: Paving the road to patient-tailored therapy. Drug Resist Updat. 7:345–358. 2004. View Article : Google Scholar : PubMed/NCBI
8	O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson RW and KE; O Kane HF Williamson: Targeting death receptors in bladder, prostate and renal cancer. J Urol. 175:432–438. 2006. View Article : Google Scholar : PubMed/NCBI
9	Cheng J, Hylander BL, Baer MR, Chen X and Repasky EA: Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther. 5:1844–1853. 2006. View Article : Google Scholar : PubMed/NCBI
10	Padhye S, Dandawate P, Yusufi M, Ahmad A and Sarkar FH: Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev. 32:1131–1158. 2012. View Article : Google Scholar : PubMed/NCBI
11	Krishnaswamy M and Purushothaman KK: Plumbagin: A study of its anticancer, antibacterial & antifungal properties. Indian J Exp Biol. 18:876–877. 1980.PubMed/NCBI
12	Mishra BB, Singh DD, Kishore N, Tiwari VK and Tripathi V: Antifungal constituents isolated from the seeds of Aegle marmelos. Phytochemistry. 71:230–234. 2010. View Article : Google Scholar : PubMed/NCBI
13	Abdul KM and Ramchender RP: Modulatory effect of plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) on macrophage functions in BALB/c mice. I. Potentiation of macrophage bactericidal activity. Immunopharmacology. 30:231–236. 1995. View Article : Google Scholar : PubMed/NCBI
14	Pradeepa V, Sathish-Narayanan S, Kirubakaran SA and Senthil-Nathan S: Antimalarial efficacy of dynamic compound of plumbagin chemical constituent from Plumbago zeylanica Linn (Plumbaginaceae) against the malarial vector Anopheles stephensi Liston (Diptera: Culicidae). Parasitol Res. 113:3105–3109. 2014. View Article : Google Scholar : PubMed/NCBI
15	Checker R, Patwardhan RS, Sharma D, Menon J, Thoh M, Sandur SK, Sainis KB and Poduval TB: Plumbagin, a vitamin K3 analogue, abrogates lipopolysaccharide-induced oxidative stress, inflammation and endotoxic shock via NF-κB suppression. Inflammation. 37:542–554. 2014. View Article : Google Scholar : PubMed/NCBI
16	Sharma I, Gusain D and Dixit VP: Hypolipidaemic and antiatherosclerotic effects of plumbagin in rabbits. Indian J Physiol Pharmacol. 35:10–14. 1991.PubMed/NCBI
17	Sunil C, Duraipandiyan V, Agastian P and Ignacimuthu S: Antidiabetic effect of plumbagin isolated from Plumbago zeylanica L. root and its effect on GLUT4 translocation in streptozotocin-induced diabetic rats. Food Chem Toxicol. 50:4356–4363. 2012. View Article : Google Scholar : PubMed/NCBI
18	Son TG, Camandola S, Arumugam TV, Cutler RG, Telljohann RS, Mughal MR, Moore TA, Luo W, Yu QS, Johnson DA, et al: Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. J Neurochem. 112:1316–1326. 2010. View Article : Google Scholar : PubMed/NCBI
19	Xu KH and Lu DP: Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo. Leuk Res. 34:658–665. 2010. View Article : Google Scholar : PubMed/NCBI
20	Gaascht F, Teiten MH, Cerella C, Dicato M, Bagrel D and Diederich M: Plumbagin modulates leukemia cell redox status. Molecules. 19:10011–10032. 2014. View Article : Google Scholar : PubMed/NCBI
21	Hsu YL, Cho CY, Kuo PL, Huang YT and Lin CC: Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther. 318:484–494. 2006. View Article : Google Scholar : PubMed/NCBI
22	Shieh JM, Chiang TA, Chang WT, Chao CH, Lee YC, Huang GY, Shih YX and Shih YW: Plumbagin inhibits TPA-induced MMP-2 and u-PA expressions by reducing binding activities of NF-kappaB and AP-1 via ERK signaling pathway in A549 human lung cancer cells. Mol Cell Biochem. 335:181–193. 2010. View Article : Google Scholar : PubMed/NCBI
23	Aziz MH, Dreckschmidt NE and Verma AK: Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 68:9024–9032. 2008. View Article : Google Scholar : PubMed/NCBI
24	Kawiak A, Zawacka-Pankau J and Lojkowska E: Plumbagin induces apoptosis in Her2-overexpressing breast cancer cells through the mitochondrial-mediated pathway. J Nat Prod. 75:747–751. 2012. View Article : Google Scholar : PubMed/NCBI
25	Kuo PL, Hsu YL and Cho CY: Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther. 5:3209–3221. 2006. View Article : Google Scholar : PubMed/NCBI
26	Lee JH, Yeon JH, Kim H, Roh W, Chae J, Park HO and Kim DM: The natural anticancer agent plumbagin induces potent cytotoxicity in MCF-7 human breast cancer cells by inhibiting a PI-5 kinase for ROS generation. PLoS One. 7:e450232012. View Article : Google Scholar : PubMed/NCBI
27	Sinha S, Pal K, Elkhanany A, Dutta S, Cao Y, Mondal G, Iyer S, Somasundaram V, Couch FJ, Shridhar V, et al: Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer. 132:1201–1212. 2013. View Article : Google Scholar : PubMed/NCBI
28	Nair S, Nair RRK, Srinivas P, Srinivas G and Pillai MR: Radiosensitizing effects of plumbagin in cervical cancer cells is through modulation of apoptotic pathway. Mol Carcinog. 47:22–33. 2008. View Article : Google Scholar : PubMed/NCBI
29	Wang CCC, Chiang YM, Sung SC, Hsu YL, Chang JK and Kuo PL: Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett. 259:82–98. 2008. View Article : Google Scholar : PubMed/NCBI
30	Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, et al: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol. 23:5705–5717. 2005. View Article : Google Scholar : PubMed/NCBI
31	Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K and Kamada N: Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 77:2031–2036. 1991.PubMed/NCBI
32	Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science. 276:111–113. 1997. View Article : Google Scholar : PubMed/NCBI
33	Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, et al: TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:5386–5397. 1997. View Article : Google Scholar : PubMed/NCBI
34	Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2:420–430. 2002. View Article : Google Scholar : PubMed/NCBI
35	Fulda S: Cell death in hematological tumors. Apoptosis. 14:409–423. 2009. View Article : Google Scholar : PubMed/NCBI
36	Castro FA, Mariani D, Panek AD, Eleutherio EC and Pereira MD: Cytotoxicity mechanism of two naphthoquinones (menadione and plumbagin) in Saccharomyces cerevisiae. PLoS One. 3:e39992008. View Article : Google Scholar : PubMed/NCBI
37	Sun J and McKallip RJ: Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression. Leuk Res. 35:1402–1408. 2011. View Article : Google Scholar : PubMed/NCBI
38	Franco R and Cidlowski JA: Glutathione efflux and cell death. Antioxid Redox Signal. 17:1694–1713. 2012. View Article : Google Scholar : PubMed/NCBI
39	Inbaraj JJ and Chignell CF: Cytotoxic action of juglone and plumbagin: A mechanistic study using HaCaT keratinocytes. Chem Res Toxicol. 17:55–62. 2004. View Article : Google Scholar : PubMed/NCBI
40	Li J, Shen Q, Peng R, Chen R, Jiang P, Li Y, Zhang L and Lu J: Plumbagin enhances TRAIL-mediated apoptosis through up-regulation of death receptor in human melanoma A375 cells. J Huazhong Univ Sci Technol. 30:458–463. 2010. View Article : Google Scholar
41	von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, et al: Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell. 27:561–573. 2015. View Article : Google Scholar : PubMed/NCBI
42	Turella P, Cerella C, Filomeni G, Bullo A, De Maria F, Ghibelli L, Ciriolo MR, Cianfriglia M, Mattei M, Federici G, et al: Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res. 65:3751–3761. 2005. View Article : Google Scholar : PubMed/NCBI
43	McKallip RJ, Lombard C, Sun J and Ramakrishnan R: Plumbagin-induced apoptosis in lymphocytes is mediated through increased reactive oxygen species production, upregulation of Fas, and activation of the caspase cascade. Toxicol Appl Pharmacol. 247:41–52. 2010. View Article : Google Scholar : PubMed/NCBI
44	Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B and Daniel PT: Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood. 97:1378–1387. 2001. View Article : Google Scholar : PubMed/NCBI